{
    "Rank": 235,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00633750",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "VICC BRE 0222"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "VU-VICC-BRE-0222"
                        },
                        {
                            "SecondaryId": "VU-VICC-020448"
                        },
                        {
                            "SecondaryId": "P50CA098131",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P50CA098131"
                        },
                        {
                            "SecondaryId": "R01CA080195",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/R01CA080195"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Vanderbilt-Ingram Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery",
                "OfficialTitle": "Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Na\u00efve Operable Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2012",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "August 2002"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "October 2007",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2007",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "March 11, 2008",
                "StudyFirstSubmitQCDate": "March 11, 2008",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "March 12, 2008",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "May 1, 2012",
                "ResultsFirstSubmitQCDate": "August 2, 2012",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "September 5, 2012",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "August 2, 2012",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 5, 2012",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Carlos L. Arteaga",
                    "ResponsiblePartyInvestigatorTitle": "Professor of Medicine and Cancer Biology, Associate Director of Clinical Research, Director VICC Breast Program, Medical Oncologist",
                    "ResponsiblePartyInvestigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Vanderbilt-Ingram Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.\n\nPURPOSE: This phase II trial is studying how well erlotinib works in treating patients with breast cancer that can be removed by surgery.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nTo determine the in situ antitumor effect of neoadjuvant erlotinib hydrochloride as measured by a reduction in Ki67 and/or an increase in terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)-positive tumor cells in patients with treatment-naive, operable breast cancer.\n\nSecondary\n\nTo identify a molecular profile, based on measurements of Estrogen Receptor (ER), Epidermal Growth Factor Receptor (EGFR), and a Human Epithelial Growth Factor Receptor-2(HER2), and protein expression profiles in patients with treatment-na\u00efve, operable breast cancer that is responsive to erlotinib hydrochloride.\nTo correlate tumor concentrations of erlotinib hydrochloride with serum levels immediately before surgery.\n\nOUTLINE: This is a multi-center study.\n\nPatients receive oral erlotinib hydrochloride once daily for 5-14 days. Patients then undergo surgical resection within 24 hours after the last dose of erlotinib hydrochloride.\n\nTumor tissue samples are collected at baseline and during surgery for correlative laboratory studies. Tissue samples are stained for ER, HER2, and EGFR levels, proliferation (Ki67), and apoptosis (TUNEL) by immunohistochemistry. Levels of erlotinib hydrochloride in tissue samples are measured by matrix-assisted laser desorption/ionization mass spectrometry. Blood samples are collected on the day of surgery. Levels of erlotinib hydrochloride in blood samples are measured by liquid chromatography/mass spectrometry.\n\nPatients are followed within 6 weeks after surgery."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage I breast cancer",
                        "stage II breast cancer",
                        "stage IIIA breast cancer",
                        "stage IIIB breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "50",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Tarceva",
                            "ArmGroupType": "Experimental",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: erlotinib hydrochloride",
                                    "Genetic: TUNEL assay",
                                    "Genetic: protein expression analysis",
                                    "Other: immunohistochemistry staining method",
                                    "Other: laboratory biomarker analysis",
                                    "Other: liquid chromatography",
                                    "Other: mass spectrometry",
                                    "Other: matrix-assisted laser desorption ionization mass spectrometry",
                                    "Procedure: therapeutic conventional surgery"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "erlotinib hydrochloride",
                            "InterventionDescription": "Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "OSI-774",
                                    "erlotonib"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Genetic",
                            "InterventionName": "TUNEL assay",
                            "InterventionDescription": "Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Genetic",
                            "InterventionName": "protein expression analysis",
                            "InterventionDescription": "Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "immunohistochemistry staining method",
                            "InterventionDescription": "Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "laboratory biomarker analysis",
                            "InterventionDescription": "Used to assess level of expression of genetic markers in pre-therapy and surgical specimens",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "liquid chromatography",
                            "InterventionDescription": "Used to determine blood plasma levels of Erlotinib on the day of surgery",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "(LC/MS)"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "mass spectrometry",
                            "InterventionDescription": "Used to determine blood plasma levels of Erlotinib on the day of surgery",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "(LC/MS)"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "matrix-assisted laser desorption ionization mass spectrometry",
                            "InterventionDescription": "After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "MALDI MS"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "therapeutic conventional surgery",
                            "InterventionDescription": "Surgical treatment will occur within 24-hours following completion of therapy.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Tarceva"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva",
                            "PrimaryOutcomeDescription": "In situ anti-tumor effect of Tarceva as measured by a minimum 75% reduction in Ki67 compared to pre-treatment tumor cells in patients with operable breast cancer.",
                            "PrimaryOutcomeTimeFrame": "5-14 days"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Molecular Profile of Participants Who Are Responsive to Tarceva",
                            "SecondaryOutcomeDescription": "Determined by estrogen receptor status (ER) and human epidermal growth factor receptor 2 (HER2) status, which are measured by staining of 200-500 tumor cells and noting the number stained. Positive = > 10% of cell show staining, negative = < 10% of cells show staining",
                            "SecondaryOutcomeTimeFrame": "at 5-14 days"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Average Post-treatment Plasma Level of Erlotinib Hydrochloride",
                            "SecondaryOutcomeDescription": "Post-treatment plasma level in \u00b5mol/L of erlotinib hydrochloride",
                            "SecondaryOutcomeTimeFrame": "After last dose of Tarceva, at 5-14 days, and before surgery"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nClinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma\n\nDiagnosis may be made by fine needle aspiration cytology or core biopsy\n\nA repeat core biopsy is not required for patients who have a paraffin embedded diagnostic core biopsy specimen available for immunohistochemical staining\n\nExclusion Criteria:\n\nPatients with locally advanced disease who are planning to undergo preoperative neoadjuvant therapy are not eligible*\n\nLocally advanced disease includes any of the following:\n\nPrimary tumor \u2265 5 cm (T3)\nTumor of any size with direct extension to the chest wall or skin (T4a-c)\nInflammatory breast cancer (T4d)\nFixed axillary lymph node metastases (N2)\nMetastasis to ipsilateral internal mammary node (N3) NOTE: *Patients with primary tumors \u2265 5 cm (T3) or tumors involving the chest wall or skin who are not candidates for preoperative chemotherapy or who decline preoperative chemotherapy are eligible\n\nMeasurable residual tumor at the primary site\n\nMeasurable disease is defined as any mass that can be reproducibly measured by physical examination\nPlanning to undergo surgical treatment with either segmental resection or total mastectomy\nPatients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer\nNo locally recurrent breast cancer\nNo evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)\nHormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nMenopausal status not specified\nEastern Cooperative Oncology Group (ECOG) performance status 0-1\nANC \u2265 1,000/mm^3\nCreatinine \u2264 1.5 times upper limit of normal (ULN)\nTotal bilirubin \u2264 1.5 times ULN\nSerum glutamic oxaloacetic transminase (SGOT) and serum glutamic pyruvic transminase (SGPT) \u2264 1.5 times ULN\nMust be at least 18 years old\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo serious medical illness that, in the judgement of the treating physician, places the patient at high risk of operative mortality\n\nPRIOR CONCURRENT THERAPY:\n\nSee Disease Characteristics\nNo prior chemotherapy for this primary breast cancer\nAt least 7 days since prior tamoxifen or raloxifene as a preventive agent",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Carlos L. Arteaga, MD",
                            "OverallOfficialAffiliation": "Vanderbilt-Ingram Cancer Center",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "University of Alabama, Birmingham",
                            "LocationCity": "Birmingham",
                            "LocationState": "Alabama",
                            "LocationZip": "35249",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Dana-Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Lineberger Comprehensive Cancer Center",
                            "LocationCity": "Chapel Hill",
                            "LocationState": "North Carolina",
                            "LocationZip": "27514",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Meharry Medical College",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37208",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Vanderbilt-Ingram Cancer Center",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37232",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "54 participants were initially consented for this study. Four were determined to be ineligible. Three participants withdrew from the study before beginning.",
                "FlowRecruitmentDetails": "Recruitment period = 8/28/2002 through 10/16/2007",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Tarceva",
                            "FlowGroupDescription": "Tarceva given by mouth at a dose of 150 mg/day for 5-14 days. Participants are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "47"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "42"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "5"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Adverse Event",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Tarceva",
                            "BaselineGroupDescription": "Tarceva given by mouth at a dose of 150 mg/day for 5-14 days. Participants are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "47"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "36"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "56",
                                                                "BaselineMeasurementSpread": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "47"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "47"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva",
                            "OutcomeMeasureDescription": "In situ anti-tumor effect of Tarceva as measured by a minimum 75% reduction in Ki67 compared to pre-treatment tumor cells in patients with operable breast cancer.",
                            "OutcomeMeasurePopulationDescription": "Patients who received the study drug and who had available pre- and post-treatment tissue.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureAnticipatedPostingDate": "07/2010",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "5-14 days",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Tarceva",
                                        "OutcomeGroupDescription": "Following a pre-treatment core breast biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants undergo a post-treatment resection of their tumor."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "34"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Molecular Profile of Participants Who Are Responsive to Tarceva",
                            "OutcomeMeasureDescription": "Determined by estrogen receptor status (ER) and human epidermal growth factor receptor 2 (HER2) status, which are measured by staining of 200-500 tumor cells and noting the number stained. Positive = > 10% of cell show staining, negative = < 10% of cells show staining",
                            "OutcomeMeasurePopulationDescription": "Participants with available pre- and post-treatment tissue and who demonstrated a post-treatment decrease in Ki67 levels compared to their pre-treatment levels",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "at 5-14 days",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Tarceva",
                                        "OutcomeGroupDescription": "Following a pre-treatment core biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants undergo a post-treatment resection of their tumor."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "8"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Estrogen receptor positive",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Estrogen receptor negative",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "HER-2 positive",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "HER-2 negative",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Average Post-treatment Plasma Level of Erlotinib Hydrochloride",
                            "OutcomeMeasureDescription": "Post-treatment plasma level in \u00b5mol/L of erlotinib hydrochloride",
                            "OutcomeMeasurePopulationDescription": "Participants with blood taken within 24 hours of last dose of erlotinib and before surgery",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Mean",
                            "OutcomeMeasureDispersionType": "Standard Deviation",
                            "OutcomeMeasureUnitOfMeasure": "\u00b5mol/L",
                            "OutcomeMeasureTimeFrame": "After last dose of Tarceva, at 5-14 days, and before surgery",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Tarceva",
                                        "OutcomeGroupDescription": "Following a pre-treatment core biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants have their blood drawn and then undergo surgical resection of their tumor."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "30"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "8.8",
                                                                "OutcomeMeasurementSpread": "7.4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Tarceva",
                            "EventGroupDescription": "Tarceva given by mouth at a dose of 150 mg/day for 5-14 days. Participants are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.",
                            "EventGroupSeriousNumAffected": "1",
                            "EventGroupSeriousNumAtRisk": "47",
                            "EventGroupOtherNumAffected": "44",
                            "EventGroupOtherNumAtRisk": "47"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Pulmonary ebmolisim",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Abdominal pain",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Alkaline phosphatase",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Allergic rhinitis",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Arrhythmia",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Arthiritis",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blurred vision",
                            "OtherEventOrganSystem": "Eye disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cough",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "15",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hemoglobin",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypercalcemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperglycemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypertension",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypothyroidism",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Infection (without neutropenia)",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Insomnia",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Joint, muscle or bone pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mood Changes - depression",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mood Changes-anxiety/agitation",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mucositis",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "19",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "29",
                                        "OtherEventStatsNumAffected": "29",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "SGPT (ALT)",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hot flashes/flushes",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "High cholesterol",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sinus infection",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "47"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Carlos Arteaga, M.D.",
                    "PointOfContactOrganization": "Vanderbilt-Ingram Cancer Center",
                    "PointOfContactPhone": "(615) 936-1919"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069347",
                            "InterventionMeshTerm": "Erlotinib Hydrochloride"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M11590",
                            "InterventionBrowseLeafName": "Mitogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M398",
                            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
                            "InterventionBrowseLeafAsFound": "Stomach",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "T22",
                            "InterventionBrowseLeafName": "Tyrosine",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "AA",
                            "InterventionBrowseBranchName": "Amino Acids"
                        }
                    ]
                }
            }
        }
    }
}